Compare PGY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | URGN |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | 518 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 1.1B |
| IPO Year | N/A | 2016 |
| Metric | PGY | URGN |
|---|---|---|
| Price | $15.28 | $29.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $34.50 | $29.29 |
| AVG Volume (30 Days) | ★ 3.4M | 873.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $14.27 | $129.09 |
| Revenue Next Year | $14.39 | $70.96 |
| P/E Ratio | $13.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.40 | $3.42 |
| 52 Week High | $44.99 | $30.00 |
| Indicator | PGY | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.10 | 75.83 |
| Support Level | $10.78 | $17.86 |
| Resistance Level | $15.57 | $30.00 |
| Average True Range (ATR) | 0.87 | 1.84 |
| MACD | 0.12 | 0.35 |
| Stochastic Oscillator | 56.18 | 84.44 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.